Michael A Paley Fahad Edrees Satoru Kudose Joseph P Gaut Prabha Ranganathan Anitha Vijayan
Saudi J Kidney Dis Transpl
2019 Jan-Feb;30(1):226-230.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/30804286/
Anti-Inflammatory Agents / therapeutic use Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / chemically induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy Antihypertensive Agents / adverse effects Hydralazine / adverse effects Rituximab / therapeutic use
Anti-Inflammatory Agents / therapeutic use Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / chemically induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy Antihypertensive Agents / adverse effects Hydralazine / adverse effects Rituximab / therapeutic use Case Reports Antihypertensive Agents / therapeutic use Autoantibodies / blood Female Humans Hydralazine / therapeutic use Hypertension / drug therapy Middle Aged Steroids / therapeutic use Anti-Inflammatory Agents Antihypertensive Agents Autoantibodies Steroids Hydralazine Rituximab
PMC6435256
30804286
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
2019